Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

ABSTRACT: Newly diagnosed high grade serous epithelial ovarian cancer (EOC) patients are treated with radical surgery followed by adjuvant platinum and taxane combination chemotherapy. In EOC patients where upfront surgery is contraindicated for medical reasons (e.g., comorbidities or poor performance status), or where complete cytoreduction cannot be achieved, neoadjuvant chemotherapy (NACT) prior to interval debulking surgery (IDS), and adjuvant chemotherapy is an alternative therapeutic option. There is currently a lack of consensus about who are the best candidates to receive NACT, and some authors have even suggested that this approach could be harmful in a subset of patients via promotion of early chemoresistance. Standard and novel imaging techniques together with a better molecular character

SUBMITTER: Moschetta M 

PROVIDER: S-EPMC7812234 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature